-Norwegian Bionor Pharma to start trial on HIV vaccine and cancer therapy.
NORDIC BUSINESS REPORT-August 25, 2011--Norwegian Bionor Pharma to start trial on HIV vaccine and cancer therapy(C)2011 M2 COMMUNICATIONS http://www.m2.com
25 August 2011 - Norwegian company Bionor Pharma ASA (OSL:BIONOR) said today it would start a study to examine the ability of its therapeutic HIV vaccine candidate Vacc-4x to improve the immune defence in combination with cancer treatment Revlimid.
The study, expected to cost around USD1.4m, will include 24 HIV-patients who fail to regain a healthy immune defence despite that their viral load is controlled via antiretroviral (ART) therapy.
It will be placebo-controlled and double-blind.
The trial will be performed in Germany and will be preceded by an open-label dose finding study to select the most appropriate Revlimid dose.
Treatment and observation will last for 26 weeks, starting in September. Results from the study are expected in the first half of 2013.
(EUR1 = USD1.4)
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Nordic Business Report|
|Date:||Aug 25, 2011|
|Previous Article:||-Norwegian Solstad Offshore's Q2 net loss narrows.|
|Next Article:||-Novo Nordisk to expand head office in DKK1bn construction.|